The closing price of all pharmaceutical companies rose to 11.76 yuan. The stock rose by the limit at 9:25. As of the closing price, 145 million yuan had been closed, accounting for 1.73% of the circulating market value.On the issue of capital inflow data, the main funds on that day were 29.5978 million yuan, hot money funds were 35.8095 million yuan and retail funds were 18.2189 million yuan. The capital flow in the last five days is shown in the table below.This strain is a strain with hot concepts of longevity drug NMN, traditional Chinese medicine and innovative drug. On that day, the concept of longevity drug NMN increased by 3.97%, traditional Chinese medicine increased by 2.16% and innovative drug increased by 1.72%.The logic of this stock investment is as follows1. Among the top 100 enterprises in China's pharmaceutical industry, the main traditional Chinese medicine products are cardio cerebrovascular medicine compound Xueshuantong capsule, Naoshuantong capsule, respiratory medicine Zhongsheng pill, Qingre Qushi granule and compound danshen tablet; Through the subsidiary Yikang traditional Chinese medicine, we expanded the planting, trade and processing business of traditional Chinese medicine and high-end decoction pieces. In 19 years, the sales revenue of traditional Chinese medicine was 1.42 billion and 56.2%, and the sales revenue of traditional Chinese medicine and decoction pieces was 98 million and 3.9%2. Signed 10 joint R & D projects of innovative drugs with Wuxi apptec; Among them, zsp1601, an innovative drug developed jointly, is the first small molecule innovative drug approved clinically for the indication of nonalcoholic steatohepatitis in China; The compound patent of zsp1602 project, an innovative drug for the treatment of small cell lung cancer, gastric cancer, esophageal cancer and other malignant tumors, has obtained patent certificates from New Zealand and the United States; In January 21, zsp1603 was an innovative drug developed by the company for the treatment of idiopathic pulmonary fibrosis (IPF) with clear action mechanism and independent intellectual property rights3. The wholly-owned subsidiary of the company is developing NMN (- nicotinamide mononucleotide) and is currently in the trial production stageIn terms of financial status, Zhongsheng pharmaceutical's third quarter report in 2021 shows that the company's main revenue is 1.824 billion yuan, an increase of 39.17% over the same period last year. The net profit attributable to the parent company was 314 million yuan, an increase of 4.07% over the same period last year; The non net profit was 297 million yuan, an increase of 66.5% over the same period last year. In the third quarter of 2021, the main revenue of the company in the first quarter was 613 million yuan, an increase of 16.85% over the same period last year, and the net profit of the parent company in each quarter was 25.9641 million yuan, a decrease of 76.36% over the same period last year; After deducting the non net profit of 89.6612 million yuan in the quarter, the year-on-year increase was 48.19%, the debt ratio was 21.17%, the investment profit was 17.9622 million yuan, the financial expense was 3.0344 million yuan, and the gross profit margin was 66.96%.According to the securities Star evaluation and analysis tool, Zhongsheng Pharmaceutical (002317) has a good company evaluation of 2.5 stars, a good price evaluation of 2.5 stars, and a comprehensive evaluation of the evaluation value of 2.5 stars. (rating range (Star 1-star 5, highest star 5) the stock has been rated by an agency and bought a rating in the last 90 days. The average target price of the agency in the past 90 days is 11.5; the net financing outflow in the past three months is 12.295 million, and the financing balance decreases; the net inflow of securities lending is 3.4217 million, and the securities lending balance increases.

トップ   編集 凍結 差分 バックアップ 添付 複製 名前変更 リロード   新規 一覧 単語検索 最終更新   ヘルプ   最終更新のRSS
Last-modified: 2021-12-04 (土) 20:27:12 (45d)